RxDoctor Payments Data

Robert Washington, MD

Internal Medicine · Los Angeles, CANPI 1295702637

Payments from drug & device makers

$2,948in general payments, 2019–2025

Across 148 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$688
  • Bayer$443
  • Avanir Pharmaceuticals, Inc.$304
  • Lilly USA, LLC$276
  • Arbor Pharmaceuticals, Inc.$185
  • Novo Nordisk$149
  • plus $903 from 18 others

What the payments were for

  • Food & beverage$2,92799%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,948 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$50,059
Medicare patients
79
Services billed
369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$117,666
TrulicityDulaglutide41$68,521
JanuviaSitagliptin Phosphate70$64,921
Diclofenac Sodium56$62,803
KerendiaFinerenone47$51,800
TradjentaLinagliptin32$39,590
MyrbetriqMirabegron29$29,500
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$24,673
JardianceEmpagliflozin13$20,477
XareltoRivaroxaban18$19,941
EliquisApixaban18$18,170
EdarbyclorAzilsartan Med/Chlorthalidone15$10,309
Diclofenac Potassium11$5,947
Icosapent Ethyl35$5,848
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen225$5,514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$149$117,666116 claims
Lilly USA, LLCTrulicity$276$68,52141 claims
Boehringer IngelheimTradjenta, Jardiance$21$60,06745 claims
BayerKerendia$443$51,80047 claims
Astellas Pharma US IncMyrbetriq$45$29,50029 claims
GSKTrelegy Ellipta$99$24,67327 claims
PfizerEliquis$84$18,17018 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$185$10,30915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →